| Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin ZM Al‐Majdoub, B Achour, N Couto, M Howard, Y Elmorsi, D Scotcher, ... FEBS letters 594 (23), 4134-4150, 2020 | 25 | 2020 |
| Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: applications in translational pharmacology and recommendations for best practice E El-Khateeb, AM Vasilogianni, S Alrubia, ZM Al-Majdoub, N Couto, ... Pharmacology & Therapeutics 203, 107397, 2019 | 23 | 2019 |
| Toxicity assessment and comparison of the land snail's Cornu aspersum responses against CuO nanoparticles and ZnO nanoparticles K Feidantsis, S Kalogiannis, A Marinoni, AM Vasilogianni, C Gkanatsiou, ... Comparative biochemistry and physiology part C: Toxicology & pharmacology …, 2020 | 18 | 2020 |
| Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects AM Vasilogianni, ZM Al‐Majdoub, B Achour, SA Peters, ... British Journal of Clinical Pharmacology 88 (4), 1811-1823, 2022 | 16 | 2022 |
| Hepatic scaling factors for in vitro–in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis AM Vasilogianni, B Achour, D Scotcher, SA Peters, ZM Al-Majdoub, ... Drug Metabolism and Disposition 49 (7), 563-571, 2021 | 12 | 2021 |
| Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease AM Vasilogianni, E El-Khateeb, ZM Al-Majdoub, S Alrubia, ... Journal of Proteomics 263, 104601, 2022 | 9 | 2022 |
| Quantitative proteomics of hepatic drug‐metabolizing enzymes and transporters in patients with colorectal cancer metastasis AM Vasilogianni, ZM Al‐Majdoub, B Achour, S Annie Peters, J Barber, ... Clinical Pharmacology & Therapeutics 112 (3), 699-710, 2022 | 8 | 2022 |
| A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins AM Vasilogianni, E El-Khateeb, B Achour, S Alrubia, A Rostami-Hodjegan, ... Journal of Proteomics 261, 104572, 2022 | 5 | 2022 |
| Label-free but still constrained: assessment of global proteomic strategies for the quantification of hepatic enzymes and transporters J Barber, ZM Al-Majdoub, N Couto, AM Vasilogianni, A Tillmann, ... Drug Metabolism and Disposition 50 (6), 762-769, 2022 | 3 | 2022 |
| Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis AM Vasilogianni, ZM Al-Majdoub, B Achour, SA Peters, ... Frontiers in Oncology 13, 1010563, 2023 | 1 | 2023 |
| Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver AM Vasilogianni, S Alrubia, E El-Khateeb, ZM Al-Majdoub, N Couto, ... Molecular Omics 20 (2), 115-127, 2024 | | 2024 |
| Quantitative proteomics of pharmacokinetics (PK) and pharmacodynamics (PD) targets in liver, small intestine, colon, appendiceal and peritoneal cancer AM Vasilogianni, C Demonacos, O Aziz, SA Peters, J Barber, ... | | 2023 |
| Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Liver Metastasis A Vasilogianni, Z Al-Majdoub, B Achour, S Peters, J Barber, ... EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 78 (SUPPL 1), S6-S6, 2022 | | 2022 |
| Impact of Gastrointestinal (Gi) and Hepatic Cancer on Enzyme and Transporter Abundance Contributing to Variability in Drug Exposure AM Vasilogianni PQDT-Global, 2021 | | 2021 |
